Table 1 Baseline characteristics of haemorrhagic reports associated with lenvatinib, pembrolizumab and combination therapy from 2015 to 2024Q1
Characteristics | Report number, N (%) | |||
|---|---|---|---|---|
Lenvatinib | Pembrolizumab | Combination therapy | ||
Number of reports | 1188 | 952 | 420 | |
Gender | Female | 435(36.62) | 442(46.43) | 243(57.86) |
| Â | Male | 727(61.2) | 482(50.63) | 174(41.43) |
| Â | Unknown or missing | 26(2.19) | 28(2.94) | 3(0.71) |
Age (years) | < 18 | 6(0.51) | 10(1.05) | 4(0.95) |
|  | 18 ≤ and ≤ 64 | 418(35.19) | 295(30.99) | 173(41.19) |
|  | > 64 | 568(47.81) | 395(41.49) | 190(45.24) |
| Â | Unknown or missing | 196(16.5) | 252(26.47) | 53(12.62) |
Serious outcome | Death | 227(19.11) | 132(13.87) | 72(17.14) |
| Â | Life-threatening | 45(3.79) | 35(3.68) | 13(3.1) |
| Â | Hospitalization | 751(63.22) | 262(27.52) | 267(63.57) |
| Â | Disability | 13(1.09) | 20(2.1) | 2(0.48) |
| Â | Others | 152(12.79) | 503(52.84) | 66(15.71) |
Reported Countries (Top five) | Japan | 465(39.14) | 396(41.6) | 82(19.52) |
| Â | Americas | 400(33.67) | 256(26.89) | 117(27.86) |
| Â | China | 107(9.01) | 18(1.89) | 29(6.9) |
| Â | Canada | 27(2.27) | 18(1.89) | 12(2.86) |
| Â | France | 17(1.43) | 36(3.78) | 20(4.76) |
Reported Person | Physician | 647(54.46) | 461(48.42) | 325(77.38) |
| Â | Consumer | 413(34.76) | 338(35.5) | 71(16.9) |
| Â | Pharmacist | 54(4.55) | 51(5.36) | 12(2.86) |
| Â | Other health-professional | 45(3.79) | 51(5.36) | 11(2.62) |
| Â | Unknown | 29(2.44) | 51(5.36) | 1(0.24) |
Reporting year | 2015 | 26(2.19) | 29(3.05) | / |
| Â | 2016 | 60(5.05) | 34(3.57) | / |
| Â | 2017 | 70(5.89) | 50(5.25) | 4(0.95) |
| Â | 2018 | 149(12.54) | 89(9.35) | 4(0.95) |
| Â | 2019 | 210(17.68) | 102(10.71) | 27(6.43) |
| Â | 2020 | 180(15.15) | 89(9.35) | 51(12.14) |
| Â | 2021 | 154(12.96) | 95(9.98) | 63(15) |
| Â | 2022 | 138(11.62) | 148(15.55) | 101(24.05) |
| Â | 2023 | 175(14.73) | 252(26.47) | 144(34.29) |
| Â | 2024Q1 | 26(2.19) | 64(6.72) | 26(6.19) |